

Symposium Speakers



Eric Wallace, MD-UAB



Melanie Sivley,
OD-UAB



Peter Harris, PhD-Mayo Clinic



Michal Mrug, MD-UAB



Thomas Natoli, PhD-
Genzyme Corporation



Robert Weiss, MD-UCD

Welcome Presenters



Anupam Agarwal, MD-UAB



Brad Yoder, PhD-UAB

Summary & Conclusions

Presenter



David G. Warnock, MD-UAB

UAB MEDICINE/NEPHROLOGY

**MINI-SYMPOSIUM
ON FABRY
DISEASE AND
POLYCYSTIC
KIDNEY DISEASE
PROSPECTS FOR
IMPROVED CARE**

**Tuesday
November 18, 2014
10:00 AM
FINLEY COMPASS BANK
CONFERENCE CENTER
(behind the Kaul Human
Genetics Building)
Birmingham, Alabama 35294**

*UAB
MEDICINE/NEPHROLOGY*

***Box lunch will be provided to registrants:
Contact Katrina Moore to register for
lunch and the symposium by***

Thursday, November 13, 2014

krmoore@uab.edu or 975-7583

Program Overview

OBJECTIVES

- a) Review the current unmet needs in the treatment of Fabry disease
- b) Review the current unmet needs in the treatment of Autosomal Dominant Polycystic Kidney Disease

FABRY

c) Review the animal model of polycystic kidney disease

&

POLYCYSTIC KIDNEY

d) Review the metabolomics pathways and mechanisms of action of inhibitors of glucosylceramide synthase.

DISEASE

Expected Improvements and Increase in Knowledge.

Through expert presentations, interactions, discussions, the following expectations will be realized

- a) Enhance communications and understanding of the basic cellular mechanisms involved in glucosylceramide synthase inhibition will promote collaborations, and research projects that will bridge the knowledge gaps that currently exist
- b) Enhanced communications and understanding of the unmet clinical needs in Fabry Disease and polycystic kidney disease will promote collaborations and clinical initiatives that will further the understanding and treatment options for patients with Fabry nephropathy and patients with autosomal dominant polycystic kidney disease

*Supported by an unrestricted educational grant from Genzyme Corporation. Sponsored by the Nephrology Research and Training Center the O'Brien Center for Acute Kidney Injury Research (P30 DK079337) and the Hepato/Renal Fibrocystic Diseases Core Center (P30 DK074038). CME accreditation through the NRTC (RSS-14938)

The University of Alabama School of Medicine is accredited by the Accreditation Council for Council for Continuing Medical Education to provide continuing medical education for physicians. The University of Alabama School of Medicine designates this Regularly Scheduled Series for a maximum of 1 AMA PRA Category 1 credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. The University Of Alabama School of Medicine is an equal opportunity/affirmative action.

AGENDA

10:00 AM Welcome

Anupam Agarwal, MD—Director of Nephrology and the UAB/UCSD O'Brien Core Center for Acute Kidney Injury Research

Brad Yoder, PhD—Director, Hepato/Renal Fibrocystic Diseases Core Center

10:15 AM Fabry Disease; 10 years of Enzyme Replacement Therapy (ERT) and the Current Unmet Clinical Needs

Eric Wallace, MD-UAB

10:45 AM Novel Ocular Findings in Classically Affected Male Fabry Patients After Long-Term ERT

Melanie Sivley, OD—UAB

11:15 AM “ADPKD Genetic Complexity, and Experimental Therapies”

Peter Harris, PhD—Mayo Clinic

12:00 NOON Networking Lunch

12:30 PM Mouse Models of Polycystic Kidney Disease

Michal Mrug, MD—UAB

1:15 PM “Glycosphingolipid Dysregulation in Cystic Kidney Disease”

Thomas Natoli, PhD—Genzyme Corporation

2:00 PM Metabolomics Analyses in Renal Cystic Disease

Robert Weiss, MD—UCD

2:45 PM Summary and Conclusions; Quo Vadis?

David G. Warnock, MD-UAB

3:00 PM Open Discussion

3:30 PM Adjourn

Background Information

Agalsidase-beta is currently available for the treatment of Fabry disease in the US, and clinical experience with enzyme replacement therapy (ERT) has accumulated with its use since its approval in April 2003. There is a significant reduction in severe target organ events (kidney, heart, brain) with ERT after an initial treatment period of approximately 6 months (lag time to benefit). (1) Longer-term results have shown a marked reduction in progression to end-stage renal disease; hence, the natural history of Fabry disease has been changed, at least for males with non-sense mutations (classic phenotypes).

The efficacy of ERT is reflected in the clearance of endothelial GL3 deposits, (2) for which the product is licensed in the US for treating Fabry disease. Lysosomal storage diseases are currently treated with enzyme replacement therapy and more recently with small molecules that inhibit glucosylceramide synthase and reduce the concentration of the proximate substrate in the gangliocerebroside pathway (3) Analogues have been designed that cross the blood-brain barrier and are not excreted from neuronal cells through the MDR1 pathway. (4) Members of this class of small molecules are referred to as substrate reduction therapy (SRT), and have recently been approved by the FDA for treatment of type 1 Gaucher disease. A member of this same class of small molecules (GZ40 2671) is currently undergoing clinical testing in male patients with Fabry disease (Clinicaltrials.gov NCT02228460).

An intriguing connection has appeared between the lysosomal storage diseases and polycystic kidney disease. Natoli et al have reported that inhibition of glucosylceramide synthase activity ameliorates the cyst phenotype in mouse models of polycystic kidney disease. (5,6) There is para-pelvic cystic phenotype described in Fabry disease, (7,8) but not in Gaucher disease. The mTOR signaling pathway is important in polycystic kidney disease, (9) as well as controlling basic cellular functions like autophagy that are most prominent in terminally differentiated cells like podocytes, cardiomyocytes, and neurons. (10-12)

This background material highlights the knowledge gaps that exist and are obstacles to the design and execution of definitive clinical trials of SRT in both lysosomal storage diseases and polycystic kidney disease. The major unmet clinical need in Fabry disease is providing effective, bioavailable therapy for involvement of podocytes, cardiomyocytes and neurons. These cells determine the long term outcomes for renal, cardiac, and central nervous system involvement in Fabry disease, and may be more amenable to systemic therapy with oral agents than the currently available intravenously ERT.

References:

1. Warnock DG, Maruti S, Cabrera GH, et al. J Am Soc Nephrol 2014; abstract.
2. Germain D, Waldek S, Banikazemi M, et al. J Am Soc Nephrol 2007;18:1547-57.
3. Lukina E, Watman N, Dragosky M, et al. Blood Cells Mol Dis 2014.
4. Larsen SD, Wilson MW, Abe A, et al. Journal of Lipid Research 2012;53:282-91.
5. Natoli TA, Husson H, Rogers KA, et al. Hum Mol Genet 2012;21:3397-407.
6. Natoli TA, Smith LA, Rogers KA, et al. Nat Med 2010; 16:788-92.
7. Glass RB, Astrin KH, Norton KL, et al. Fabry Disease: J Comput Assist Tomogr 2004;28:158-68.
8. Riles M, Bettis KE, Choyke P, et al. Kidney Int 2004;66:978-82
9. Ibraghimov-Beskrovnyaya O, Natoli TA. Trends Mol Med 2011;17:625-33.
10. Grahmmer F, Haenisch N, Steinhardt F, et al. Proc Natl Acad Sci U S A 2014;111:E2817-26.
11. Grahmmer F, Wanner N, Huber TB Nephrol Dial Transplant 2014;29 Suppl 1:i9-118.
12. Wanner N, Hartleben B, Herbach N, et al. J Am Soc Nephrol 2014;25:707-16.